SAN DIEGO, CA – February 8, 2018

AnaBios announced today a partnership with Sanofi to develop a new treatment for atrial fibrillation. The program will focus on compounds designed to modulate a novel cardiac ion channel target.

Through this agreement, AnaBios will acquire development and commercialization rights to an entire family of promising compounds addressing the global atrial fibrillation market, which is estimated to reach $16.17 billion by 2020 according to a recent report by Grand View Research.

“Our new partnership with Sanofi, a global healthcare leader, validates the tremendous accomplishments of AnaBios in developing a human tissue- and cell-based technology for accurately predicting human clinical responses at an early development stage,” said Andre Ghetti, Chief Executive Officer of AnaBios. “We will employ our CardioPRIME™ technology to optimize the efficacy and safety of this novel class of molecules for the potential treatment of atrial fibrillation, a condition which affects over 33 million patients worldwide and remains difficult to treat.”

CardioPRIME™ is part of AnaBios’ broad portfolio of ex-vivo human safety and efficacy evaluation technology, which employs primary human cells and tissues—maintained in a fully-functional state outside of the body—for preclinical laboratory study of drug activity.

In a recently published peer-reviewed article, the CardioPRIME™ technology demonstrated the ability to predict human clinical outcomes with greater than 95% accuracy (Nguyen et al, Frontiers in Physiology 2017).

About AnaBios

Located in San Diego, CA, AnaBios aims to establish the safety and efficacy of novel compounds through its advanced, human-focused translational technologies.  AnaBios primarily focuses on areas of high, unmet medical need, including cardiac disease and safety, pain, itch and kidney disease.  In addition to working with Fortune 500 biotech companies, CROs and academia, AnaBios drives an internal drug discovery platform via in-licensed programs from partners in the pharmaceutical industry. For more information about AnaBios, visit